Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation

The Pathogenesis of the Antiphospholipid Syndrome

(2013) Bill Giannakopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study

(2012) Savino Sciascia et al.   INFLAMMATION RESEARCH

Identification of Fibrin Clot-Bound Plasma Proteins

(2012) Simone Talens et al.   PLoS One

Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism

(2012) Marek Zolcinski et al.   THROMBOSIS AND HAEMOSTASIS

A history of early stent thrombosis is associated with prolonged clot lysis time

(2012) Oksana Pankiw-Bembenek et al.   THROMBOSIS AND HAEMOSTASIS

Reduced Thrombin Formation and Altered Fibrin Clot Properties Induced by Polyunsaturated Omega-3 Fatty Acids on Top of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention (OMEGA-PCI Clot)

(2011) Grzegorz Gajos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Fibrin Clot Structure and Function

(2011) Anetta Undas et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study

(2011) V. Pengo et al.   BLOOD

Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment

(2011) A. Tripodi et al.   JOURNAL OF INTERNAL MEDICINE

Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1

(2010) M. E. Meltzer et al.   BLOOD

Neurological manifestations of antiphospholipid syndrome

(2010) Carlos E. M. Rodrigues et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation

(2010) Masahiro Ieko et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Antiphospholipid syndrome

(2010) Guillermo Ruiz-Irastorza et al.   LANCET

Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis

(2010) Beata Kwasny-Krochin et al.   THROMBOSIS RESEARCH

Impaired Fibrinolysis in the Antiphospholipid Syndrome

(2010) Katie A. Krone et al.   Current Rheumatology Reports

Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System

(2009) R.A. Ajjan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

β2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation

(2009) Chunya Bu et al.   ARTHRITIS AND RHEUMATISM

Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives

(2009) A. Undas et al.   BLOOD

Update of the guidelines for lupus anticoagulant detection

(2009) V. PENGO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Antiphospholipid Syndrome as a Neurological Disease

(2009) Yoav Arnson et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Heritability of Clot Formation

(2009) Kristina Standeven et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke

(2009) Anetta Undas et al.   STROKE

Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis

(2008) PP Chen et al.   LUPUS

Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress

(2007) Anetta Undas et al.   ATHEROSCLEROSIS